Xponance Inc. Has $355,000 Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Xponance Inc. cut its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 4.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 8,148 shares of the life sciences company’s stock after selling 367 shares during the quarter. Xponance Inc.’s holdings in Integra LifeSciences were worth $355,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Integra LifeSciences by 1.0% during the third quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock worth $273,435,000 after purchasing an additional 72,294 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Integra LifeSciences by 19.5% during the third quarter. Victory Capital Management Inc. now owns 1,465,115 shares of the life sciences company’s stock worth $55,953,000 after purchasing an additional 238,816 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new position in shares of Integra LifeSciences during the third quarter worth approximately $43,034,000. Assenagon Asset Management S.A. acquired a new position in shares of Integra LifeSciences during the third quarter worth approximately $25,443,000. Finally, Glenmede Trust Co. NA lifted its position in shares of Integra LifeSciences by 45.6% during the third quarter. Glenmede Trust Co. NA now owns 306,032 shares of the life sciences company’s stock worth $11,687,000 after purchasing an additional 95,857 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Stock Down 0.2 %

Shares of NASDAQ:IART opened at $28.34 on Friday. Integra LifeSciences Holdings Co. has a 52 week low of $27.18 and a 52 week high of $56.21. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. The company has a market capitalization of $2.23 billion, a PE ratio of 34.14, a PEG ratio of 0.86 and a beta of 1.12. The company has a 50 day moving average price of $35.34 and a two-hundred day moving average price of $38.76.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The firm had revenue of $397.00 million during the quarter, compared to the consensus estimate of $399.30 million. During the same period in the previous year, the company posted $0.94 EPS. The firm’s revenue for the quarter was down .3% on a year-over-year basis. Analysts forecast that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on IART shares. StockNews.com lowered shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. JMP Securities cut their price objective on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. Truist Financial cut their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. Finally, Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price objective on the stock in a report on Wednesday, April 3rd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Integra LifeSciences has an average rating of “Hold” and a consensus price target of $44.89.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.